env-mRNA vaccine

The env-mRNA vaccine is an experimental therapeutic mRNA-based vaccine designed to treat HIV-1 infection by eliciting autologous neutralizing antibodies (aNAbs) and enhancing antibody-dependent cellular cytotoxicity (ADCC). Developed through a collaboration involving Duke University and the University of Pennsylvania, the vaccine utilizes lipid nanoparticle (LNP) technology to deliver mRNA encoding the HIV-1 CH505 gp160 envelope (env) protein trimers. The primary goal of the immunization is to target the CD4-binding site (CD4bs) on the viral envelope to control or delay viral rebound following the interruption of combination antiretroviral therapy (cART). Preclinical data presented at CROI 2026 demonstrated that while the vaccine successfully boosted functional antibody responses and reduced the viral reservoir size in rhesus macaques, it did not significantly delay the time to viral rebound after treatment interruption, suggesting a need for further optimization of epitope targeting.

Other names

HIV-1 CH505 gp160 mRNA vaccineHIV1 CH505 gp160 mRNA vaccineHIV 1 CH505 gp160 mRNA vaccineCH505 gp160 mRNA-LNP vaccineCH-505 gp160 mRNA-LNP vaccineCH 505 gp160 mRNA-LNP vaccineHIV-1 CH505 gp160 trimers delivered by mRNA-LNPHIV1 CH505 gp160 trimers delivered by mRNA-LNPHIV 1 CH505 gp160 trimers delivered by mRNA-LNP